Study of MASCoD, a New Screening Tool for Detecting and Monitoring Subjective Cognitive Decline Evaluating Its Ability to Predict Severe Cognitive Impairment and Guide Cognitive Training

What this Trial Is About

Subjective cognitive decline SCD is a condition where individuals experience cognitive difficulties without these issues being detected through standard diagnostic or neuropsychological tests. This condition can affect a persons frailty and quality of life and may be an early sign of more severe cognitive problems like mild cognitive impairment or dementia. Researchers aim to evaluate a new screening tool called MASCoD Multidimensional Assessment of Subjective Cognitive Decline to detect and monitor SCD and to predict the risk of developing severe cognitive decline over time. The study involves outpatients who will undergo a detailed evaluation including neuropsychological testing and brain imaging with 18F-FDG-PET. Participants will then be randomly assigned to one of two groups an experimental group receiving cognitive training using technological devices Neurotablet supervised by a neuropsychologist, or a wait list control group that will not receive training initially but will be offered the same cognitive stimulation after the study period. The cognitive training consists of about 30 minutes of offline exercises five days a week for eight weeks and a weekly one-hour face-to-face session. Participants will be assessed at baseline and again after six months to one year using the MASCoD tool and neuropsychological evaluations. The researchers will measure the validity of MASCoD by comparing its scores to brain imaging and neuropsychological results and will also evaluate its usefulness in monitoring patients over time and identifying those who may benefit most from cognitive training. The study includes safety monitoring and follow-up assessments, with participation lasting up to one year.

MASCoD - Multidimensional Assessment of Subjective Cognitive Decline